Persontilpasset medisin for kardiovaskulær, metabolsk og nyresykdom (CARMEN2026)

The CARMEN2026 call supports "Innovative presisjonsmedisinske strategier for pasienter med hjerte-karsykdom, metabolske sykdommer eller nyresykdommer" (innovative precision medicine strategies for patients with cardiovascular disease, metabolic diseases or kidney diseases). Projects may address one disease area or cut across conditions, and may focus on innovative personalised therapeutics, treatment response monitoring, or early disease risk prediction.

Eligible applicants include public sector organisations, businesses/industry (næringsliv), and research organisations. Funding rates vary by applicant type: up to 50% for the private sector and up to 100% for the public sector ("50-100 % avhengig av type søker; inntil 50 % til privat sektor og inntil 100 % til offentlig sektor").

The total call budget is approximately 38,000,000 EUR. The maximum funding amount per project is 1,500,000 EUR. The scheme is part of the European Partnership for Personalised Medicine (PerMed).

The call had a sketch (skisse) deadline of 10 February 2026 at 14:00 CET. The main application deadline is 9 June 2026 at 14:00 CEST. Applications are submitted via the PerMed partnership portal at https://www.eppermed.eu/funding-projects/calls/jtc2026/.